Cargando…

In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera

BACKGROUND: An important limiting factor in the development of centrally acting pharmaceuticals is the blood-brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a challenge for peptide drug delivery into the central nervous system (CNS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guillemyn, Karel, Kleczkowska, Patrycja, Novoa, Alexandre, Vandormael, Bart, Van den Eynde, Isabelle, Kosson, Piotr, Asim, Muhammad Faheem, Schiller, Peter W, Spetea, Mariana, Lipkowski, Andrzej W, Tourwé, Dirk, Ballet, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284447/ https://www.ncbi.nlm.nih.gov/pubmed/22289619 http://dx.doi.org/10.1186/1756-6606-5-4

Ejemplares similares

PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects
por: Kleczkowska, Patrycja, et al.
Publicado: (2010)

Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain
por: Lagard, Camille, et al.
Publicado: (2016)

One-Pot Isomerization–Cross Metathesis–Reduction (ICMR) Synthesis of Lipophilic Tetrapeptides
por: Jida, Mouhamad, et al.
Publicado: (2014)

5-Benzyl substituted 14-methoxymetopon, a high affinity μ opioid receptor agonist with potent antinociceptive activity in mice
por: Spetea, Mariana, et al.
Publicado: (2008)

The Hypnotic, Anxiolytic, and Antinociceptive Profile of a Novel µ-Opioid Agonist
por: Montes, Guilherme Carneiro, et al.
Publicado: (2017)

β(2)-Homo-Amino Acid Scan of µ-Selective Opioid Tetrapeptide TAPP
por: Tymecka, Dagmara, et al.
Publicado: (2020)

Synthesis, Biological, and Structural Explorations of New Zwitterionic Derivatives of 14-O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives
por: Spetea, Mariana, et al.
Publicado: (2018)

Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist–Neurokinin Antagonist Peptidomimetics
por: Gadais, Charlène, et al.
Publicado: (2021)

PM287. Mixtures of opioid receptor agonists and cannabinoid receptor agonists: enhanced antinociception without abuse liability
por: France, Charles P, et al.
Publicado: (2016)

The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception
por: Hill, Rob, et al.
Publicado: (2018)

Bifunctional Peptidomimetic G Protein-Biased Mu-Opioid Receptor Agonist and Neuropeptide FF Receptor Antagonist KGFF09 Shows Efficacy in Visceral Pain without Rewarding Effects after Subcutaneous Administration in Mice
por: Dumitrascuta, Maria, et al.
Publicado: (2022)

Discovery of Novel µ-Opioid Receptor Inverse Agonist from a Combinatorial Library of Tetrapeptides through Structure-Based Virtual Screening
por: Poli, Giulio, et al.
Publicado: (2019)

Biphalin—A Potent Opioid Agonist—As a Panacea for Opioid System-Dependent Pathophysiological Diseases? †
por: Redkiewicz, Patrycja, et al.
Publicado: (2021)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus
por: Dyniewicz, Jolanta, et al.
Publicado: (2020)

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking
por: Dumitrascuta, Maria, et al.
Publicado: (2021)

Synthesis and Pharmacological Activities of 6-Glycine Substituted 14-Phenylpropoxymorphinans, a Novel Class of Opioids with High Opioid Receptor Affinities and Antinociceptive Potencies
por: Spetea, Mariana, et al.
Publicado: (2011)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019)

Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists
por: Kaserer, Teresa, et al.
Publicado: (2020)

Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance
por: Mosberg, Henry I., et al.
Publicado: (2014)

Role of mu opioid receptor (MOR) agonist efficacy as a determinant of opioid antinociception in a novel assay of pain-depressed behavior in female and male mice
por: Negus, S. Stevens, et al.
Publicado: (2023)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

Modulation of G-protein activation, calcium currents and opioid receptor phosphorylation by the pH-dependent antinociceptive agonist NFEPP
por: Celik, Melih Özgür, et al.
Publicado: (2023)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
por: Day, Nathaniel, et al.
Publicado: (2022)

Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure–Activity Relationship Studies
por: Gonzalez, Simon, et al.
Publicado: (2020)

Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
por: Mititelu Tartau, Liliana, et al.
Publicado: (2021)

Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
por: Wang, Xin, et al.
Publicado: (2021)

Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966
por: Reichenbach, Zachary W., et al.
Publicado: (2022)

A ligand-based 3D pharmacophore model for the μ opioid receptor: application to the morphinan class of opioids
por: Asim, Muhammad Faheem, et al.
Publicado: (2010)

In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity
por: Matalińska, Joanna, et al.
Publicado: (2020)

Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists
por: Dumitrascuta, Maria, et al.
Publicado: (2017)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Changing Pattern of Opioid Users Attending an Opioid Agonist Treatment Clinic in North India
por: Bhat, Fazle R., et al.
Publicado: (2022)

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?
por: Weiss, R., et al.
Publicado: (2023)

Amelioration of injury-induced tissue acidosis by a nonsteroidal analgesic attenuates antinociceptive effects of the pH-dependent opioid agonist NFEPP
por: Celik, Melih Ö., et al.
Publicado: (2022)

Pharmacological Investigations of N-Substituent Variation in Morphine and Oxymorphone: Opioid Receptor Binding, Signaling and Antinociceptive Activity
por: Ben Haddou, Tanila, et al.
Publicado: (2014)

Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations
por: Edinoff, Amber N., et al.
Publicado: (2021)

Novel Mixed NOP/Opioid Receptor Peptide Agonists
por: Pacifico, Salvatore, et al.
Publicado: (2021)

Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor
por: Ben Haddou, Tanila, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u761o7tml45r9736ot6k13718s